• 1
    Chan OT, Tsai N, Wong RL, Izumi AK. The additive effects of hepatitis C infection and end-stage renal disease in porphyria cutanea tarda. Cutis 2006; 78: 397400.
  • 2
    Frank J, Poblete-Gutierrez P. Porphyria cutanea tarda–when skin meets liver. Best Pract Res Clin Gastroenterol 2010; 24: 73545.
  • 3
    Lim HW. Role of viral infection in porphyria cutanea tarda. Photodermatol Photoimmunol Photomed 1997; 13: 757.
  • 4
    Sams H, Kiripolsky MG, Bhat L, Stricklin GP. Porphyria cutanea tarda, hepatitis C, alcoholism, and hemochromatosis: a case report and review of the literature. Cutis 2004; 73: 18890.
  • 5
    Chemmanur AT, Bonkovsky HL. Hepatic porphyrias: diagnosis and management. Clin Liver Dis 2004; 8: 80738, viii.
  • 6
    Alla V, Bonkovsky HL. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 2005; 25: 46172.
  • 7
    Badenas C, To-Figueras J, Phillips JD, et al. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet 2009; 75: 34653.
  • 8
    Bonkovsky HL, Lambrecht RW. Hemochromatosis, iron overload, and porphyria cutanea tarda. In: Barton JC, Edwards CQ, eds. Hemochromatosis-Genetics, Pathophysiology, Diagnosis and Treatment, 2nd edn. Cambridge, UK: Cambridge University Press, 2000; 45367.
  • 9
    Desnick RJ, Astrin KH. The porphyrias. In: Fauci A, Braunwald E, Kasper D, eds. Harrison's: Principles of Internal Medicine, 17th edn. New York: McGraw Hill, 2008; 243444.
  • 10
    Foran SE, Abel G. Guide to porphyrias. A historical and clinical perspective. Am J Clin Pathol 2003; 119(Suppl): S8693.
  • 11
    Pietrangelo A. The porphyrias: pathophysiology. Intern Emerg Med 2010; 5(Suppl. 1): S6571.
  • 12
    Desnick RJ, Bishop DF, Sassa S, Anderson KE. Disorders of heme biosynthesis: X-linked sideroblastic anaemia and the porphyrias. In: Scriver C, ed. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw Hill, 2001; 29913062.
  • 13
    Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A 2007; 104: 507984.
  • 14
    Danton M, Lim CK. Porphomethene inhibitor of uroporphyrinogen decarboxylase: analysis by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Biomed Chromatogr 2007; 21: 6613.
  • 15
    English JC 3rd, Peake MF, Becker LE. Hepatitis C and porphyria cutanea tarda. Cutis 1996; 57: 4048.
  • 16
    Hussain I, Hepburn NC, Jones A, O'Rourke K, Hayes PC. The association of hepatitis C viral infection with porphyria cutanea tarda in the Lothian region of Scotland. Clin Exp Dermatol 1996; 21: 2835.
  • 17
    Jalil S, Grady JJ, Lee C, Anderson KE. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol 2010; 8: 297302.
  • 18
    Sarkany RP. Making sense of the porphyrias. Photodermatol Photoimmunol Photomed 2008; 24: 1028.
  • 19
    Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin. Photochem Photobiol 2008; 84: 45062.
  • 20
    Anderson KE. The porphyrias. In: Boyer T, Wright T, Manns M, eds. Zakim and Boyer's Hepatology: A Textbook of Liver Disease, 5th edn. Philadelphia: Saunders-Elsevier, 2006; 1391420.
  • 21
    Chiaverini C, Halimi G, Ouzan D, et al. Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology 2003; 206: 2126.
  • 22
    Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007; 46: 107180.
  • 23
    Azim J, McCurdy H, Moseley RH. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. World J Gastroenterol 2008; 14: 59135.
  • 24
    Cribier B, Chiaverini C, Dali-Youcef N, et al. Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboxylase and mutations of HFE gene. A case-control study. Dermatology 2009; 218: 1521.
  • 25
    Dienhart P, Sterling R. Management of hepatitis C virus in patients with porphyria cutanea tarda. Curr Hepat Rep 2005; 4: 10411.
  • 26
    Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 16619.
  • 27
    Wickliffe JK, Abdel-Rahman SZ, Lee C, et al. CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med 2011; 4: 2417.
  • 28
    Scribner A, Houck D, Huang Z, et al. Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents. Bioorg Med Chem Lett 2010; 20: 65426.
  • 29
    Wright TL, Manns M. Hepatitis C. In: Boyer T, Wright TL, Manns M, eds. Zakim and Boyer's Hepatology: A Textbook of Liver Disease, 5th edn. Philadelphia: Saunders-Elsevier, 2006; 66586.
  • 30
    Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010; 36: 91133.
  • 31
    Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J 2011; 8: 161.
  • 32
    Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 66678.
  • 33
    Chuang TY, Brashear R, Lewis C. Porphyria cutanea tarda and hepatitis C virus: a case-control study and meta-analysis of the literature. J Am Acad Dermatol 1999; 41: 316.
  • 34
    Dabrowska E, Jablonska-Kaszewska I, Bielawski KP, Falkiewicz B. Influence of hepatitis C virus (HCV) infection on porphyrin and iron metabolism in porphyria cutanea tarda (PCT) patients. Med Sci Monit 2001; 7(Suppl. 1): 1906.
  • 35
    Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39: 6207.
  • 36
    O'Reilly FM, Darby C, Fogarty J, et al. Porphyrin metabolism in hepatitis C infection. Photodermatol Photoimmunol Photomed 1996; 12: 313.
  • 37
    Kawamura Y, Akuta N, Sezaki H, et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol 2005; 40: 9016.
  • 38
    Narang T, Sendi H, Scobey M, Bonkovsky H. Iron and Hepatitis C. Curr Hepat Rep 2010; 9: 16977.
  • 39
    Lambrecht RW, Thapar M, Bonkovsky HL. Genetic aspects of porphyria cutanea tarda. Semin Liver Dis 2007; 27: 99108.
  • 40
    Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349: 3213.
  • 41
    Santos M, Clevers HC, Marx JJ. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. N Engl J Med 1997; 336: 13278.
  • 42
    Price L, Kowdley KV. The role of iron in the pathophysiology and treatment of chronic hepatitis C. Can J Gastroenterol 2009; 23: 8228.
  • 43
    Furutani T, Hino K, Okuda M, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130: 208798.
  • 44
    Fillebeen C, Muckenthaler M, Andriopoulos B, et al. Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J Hepatol 2007; 47: 1222.
  • 45
    Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 22638.
  • 46
    Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48: 14209.
  • 47
    Fujita N, Sugimoto R, Takeo M, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med 2007; 13: 97104.
  • 48
    Girelli D, Pasino M, Goodnough JB, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 2009; 51: 84552.
  • 49
    Ajioka RS, Phillips JD, Weiss RB, et al. Down-regulation of hepcidin in porphyria cutanea tarda. Blood 2008; 112: 47238.
  • 50
    Weber T, Theurich S, Christopeit M, Klapperstueck T, Behre G. Human herpesvirus-6 as an inducer of porphyria cutanea tarda: implications from a case. Transpl Infect Dis 2010; 12: 4326.
  • 51
    Sinclair PR, Gorman N, Walton HS, et al. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol 2000; 162: 607.
  • 52
    Dereure O, Jumez N, Bessis D, Gallix B, Guillot B. Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study. Acta Derm Venereol 2008; 88: 3415.
  • 53
    Linde Y, Harper P, Floderus Y, Ros AM. The prevalence of hepatitis C in patients with porphyria cutanea tarda in Stockholm, Sweden. Acta Derm Venereol 2005; 85: 1646.
  • 54
    Gil-Mosquera M, Vano-Galvan S, Gomez-Guerra R, Jaen P. Lesions on the hands, high aminotransferase levels. Cleve Clin J Med 2010; 77: 346.
  • 55
    Di Padova C, Marchesi L, Cainelli T, et al. Effects of phlebotomy on urinary porphyrin pattern and liver histology in patients with porphyria cutanea tarda. Am J Med Sci 1983; 285: 212.
  • 56
    Moran MJ, Fontanellas A, Brudieux E, et al. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection. Hepatology 1998; 27: 5849.
  • 57
    Ratnaike S, Blake D, Campbell D, Cowen P, Varigos G. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection. Australas J Dermatol 1988; 29: 38.
  • 58
    Rocchi E, Gibertini P, Cassanelli M, et al. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med 1986; 107: 3642.
  • 59
    Kostler E, Wollina U. Therapy of porphyria cutanea tarda. Expert Opin Pharmacother 2005; 6: 37783.
  • 60
    Sarkany RP. The management of porphyria cutanea tarda. Clin Exp Dermatol 2001; 26: 22532.
  • 61
    Bonkovsky HL, Naishadham D, Lambrecht RW, et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006; 131: 144051.
  • 62
    Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 2007; 10: 44455.
  • 63
    Stolzel U, Kostler E, Koszka C, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21: 15003.
  • 64
    Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997; 44: 5258.
  • 65
    Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995; 22: 24950.
  • 66
    Rossini A, Contessi G, Bozzetti F. Efficacy of iron depletion and antiviral therapy in patients with porphyria cutanea tarda (PCT) and hepatitis C virus (HCV) chronic infection. Hepatology 2004; 40: 320A.
  • 67
    Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 75968.
  • 68
    Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000; 32: 1358.
  • 69
    Fernandez I, Castellano G, De Salamanca RE, et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 2003; 38: 3149.
  • 70
    Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008; 53: 81522.
  • 71
    Scobey M, Bonkovsky HL. Iron: a putative reason for gender-based differences in chronic liver disease. In: Simizu I, ed. Female Hepatology: Impact of Female Sex Against Progression of Liver Disease. Kerala, India: Research Signpost Publishing, 2009: 97128.
  • 72
    Pianko S, McHutchison JG, Gordon SC, et al. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. J Interferon Cytokine Res 2002; 22: 4839.
  • 73
    Rulyak SJ, Eng SC, Patel K, et al. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol 2005; 100: 3327.
    Direct Link:
  • 74
    Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 2009; 24: 1906.
  • 75
    Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002; 22: 26975.
  • 76
    Ferrara F, Ventura P, Vegetti A, et al. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol 2009; 104: 60516.
  • 77
    Lindsay KL, Morishima C, Wright EC, et al. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6: 23441.
  • 78
    Lambrecht RW, Sterling RK, Naishadham D, et al. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011; 140: 1490500.
  • 79
    Hayashi H, Takikawa T, Nishimura N, et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 9868.
  • 80
    Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007; 42: 8306.
  • 81
    Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K. Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: results from a randomized, controlled trial on 40 Japanese patients. Intern Med 2007; 46: 63742.
  • 82
    Sartori M, Andorno S, Rossini A, et al. A case-control histological study on the effects of phlebotomy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2011; 23: 1178.
  • 83
    Hayashi H, Piperno A, Tomosugi N, et al. Patients with chronic hepatitis C may be more sensitive to iron hepatotoxicity than patients with HFE-hemochromatosis. Intern Med 2010; 49: 23717.
  • 84
    Alsatie M, Kwo P. Treatment of chronic hepatitis C in patients who have failed to respond to IFN or IFN and ribavirin combination therapy. Curr Hepatitis Rep 2003; 2: 329.
  • 85
    Scheuer P, Lefkowitch J. Liver Biopsy Interpretation. Philadelphia: Saunders Co, 2000.
  • 86
    Egger NG, Goeger DE, Payne DA, et al. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002; 47: 41926.
  • 87
    Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95: 156571.
  • 88
    Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol 2005; 85: 33741.
  • 89
    Nagy Z, Koszo F, Par A, et al. Hemochromatosis (HFE) gene mutations and hepatitis C virus infection as risk factors for porphyria cutanea tarda in Hungarian patients. Liver Int 2004; 24: 1620.
  • 90
    Tannapfel A, Stolzel U, Kostler E, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 2001; 439: 15.
  • 91
    Ivanova A, von Ahsen N, Adjarov D, et al. C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria. Hepatology 1999; 30: 15312.
  • 92
    Lamoril J, Andant C, Bogard C, et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 1998; 27: 84852.
  • 93
    Roberts AG, Whatley SD, Nicklin S, et al. The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology 1997; 25: 15961.
  • 94
    Herrero C, Vicente A, Bruguera M, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341: 7889.
  • 95
    Fargion S, Piperno A, Cappellini MD, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16: 13226.
  • 96
    Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28: 4049.
  • 97
    Mendez M, Rossetti MV, Del CBAM, Parera VE. The role of inherited and acquired factors in the development of porphyria cutanea tarda in the Argentinean population. J Am Acad Dermatol 2005(3 Pt. 1); 52: 41724.
  • 98
    Martinelli AL, Zago MA, Roselino AM, et al. Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am J Gastroenterol 2000; 95: 351621.
    Direct Link:
  • 99
    Caballes FR, Bonkovsky HL. Cutaneous porphyrias. In: Bacon BR, Spechler S, Forsmark C, eds. Gastroenterology and Hepatology. Wilmington, DE: Decision Support in Medicine, LLC, 2012, in press.